Clinical Uses for Botulinum Toxin
Botulinum toxin injections can improve quality of life for patients across a variety of aspects of health care, including pain management, urology, dermatology, and more.
Diagnosis & Disease Information
FDA Approves Zurzuvae, an Oral Treatment for Postpartum Depression
Zurzuvae is expected to become available in the fourth quarter of 2023 following scheduling as a controlled substance by the DEA.
Rexulti Approved for Agitation Associated With Dementia Due to Alzheimer Disease
Brexpiprazole is an atypical antipsychotic.
Pediatric Mental Disorder Risk Associated With Gender, Family Income, Obesity
This study was designed to be a current snapshot of the prevalence of and trends in mental disorders among children aged 9 to 10 years in the US.
Kratom Use in the United States: What Clinicians Should Know
We spoke with 2 experts about the use of kratom in the US for pain, mood, and anxiety-related issues, and what are the key implications for clinicians.
Hospitalization Linked With Substance Use and Psychiatric Disorders in COVID-19
Investigators sought to evaluate the association of comorbid PD and SUD with the probability of hospitalization among patients with COVID-19 in the emergency department.
Beta-Blocker Use Tied to Reductions in Violence
Seena Fazel of the University of Oxford, UK, and colleagues at the Karolinska Institute in Sweden compared the medicated and non-medicated periods of over 1.4 million beta blocker users.
Gepirone Under Review for Major Depressive Disorder
Exxua (previously named Travivo) is a novel oral serotonin 1A receptor agonist.
Rykindo Approved for Schizophrenia, Bipolar Disorder
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular).
Brexpiprazole Gets Priority Review for Agitation With Alzheimer Dementia
The sNDA is supported by data from two phase 3 studies that evaluated the efficacy and safety of brexpiprazole in patients with agitation associated with Alzheimer dementia.
- Loading...
Loading...
Loading... 
Loading...